Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist

Marcia A. Friedman, Kevin Winthrop

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis–specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues.”

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalRheumatic Disease Clinics of North America
Volume43
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Antirheumatic Agents
Immune System
Rheumatoid Arthritis
Vaccination
Vaccines
Immunosuppressive Agents
Safety
Infection
Population
Rheumatologists
Therapeutics
Vaccine Immunogenicity

Keywords

  • Anti-TNF
  • Biologic
  • DMARD
  • Efficacy
  • Immunogenicity
  • Rheumatoid arthritis
  • Rituximab
  • Vaccine

ASJC Scopus subject areas

  • Rheumatology

Cite this

Vaccines and Disease-Modifying Antirheumatic Drugs : Practical Implications for the Rheumatologist. / Friedman, Marcia A.; Winthrop, Kevin.

In: Rheumatic Disease Clinics of North America, Vol. 43, No. 1, 01.02.2017, p. 1-13.

Research output: Contribution to journalReview article

@article{cc8d16e81af043368d0b06069c480d8b,
title = "Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist",
abstract = "Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis–specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues.”",
keywords = "Anti-TNF, Biologic, DMARD, Efficacy, Immunogenicity, Rheumatoid arthritis, Rituximab, Vaccine",
author = "Friedman, {Marcia A.} and Kevin Winthrop",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.rdc.2016.09.003",
language = "English (US)",
volume = "43",
pages = "1--13",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Vaccines and Disease-Modifying Antirheumatic Drugs

T2 - Practical Implications for the Rheumatologist

AU - Friedman, Marcia A.

AU - Winthrop, Kevin

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis–specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues.”

AB - Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis–specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues.”

KW - Anti-TNF

KW - Biologic

KW - DMARD

KW - Efficacy

KW - Immunogenicity

KW - Rheumatoid arthritis

KW - Rituximab

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85001735591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001735591&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2016.09.003

DO - 10.1016/j.rdc.2016.09.003

M3 - Review article

C2 - 27890167

AN - SCOPUS:85001735591

VL - 43

SP - 1

EP - 13

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 1

ER -